2015
Racial Differences in the Use and Outcome of Neoadjuvant Chemotherapy for Breast Cancer: Results From the National Cancer Data Base
Killelea BK, Yang VQ, Wang SY, Hayse B, Mougalian S, Horowitz NR, Chagpar AB, Pusztai L, Lannin DR. Racial Differences in the Use and Outcome of Neoadjuvant Chemotherapy for Breast Cancer: Results From the National Cancer Data Base. Journal Of Clinical Oncology 2015, 33: 4267-4276. PMID: 26598753, DOI: 10.1200/jco.2015.63.7801.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsAsianBiomarkers, TumorBlack or African AmericanBreast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, LobularChemotherapy, AdjuvantComorbidityDatabases, FactualFemaleHispanic or LatinoHumansInsurance CoverageInsurance, HealthMiddle AgedNeoadjuvant TherapyNeoplasm GradingNeoplasm StagingReceptor, ErbB-2Receptors, EstrogenReceptors, ProgesteroneTreatment OutcomeTriple Negative Breast NeoplasmsUnited StatesWhite PeopleConceptsPathologic complete responseNational Cancer Data BaseNeoadjuvant chemotherapyBreast cancerEstrogen receptorWhite womenPositive tumorsAsian womenHuman epidermal growth factor receptor 2HER2-positive breast cancerEpidermal growth factor receptor 2Timing of chemotherapyClinical T stageGrowth factor receptor 2Triple-negative tumorsPatient's zip codeHigh-grade tumorsRacial differencesZip codesFactor receptor 2Chemotherapy useComorbidity indexComplete responseT stageGrade tumors
2010
Association Between Patient and Tumor Characteristics With Clinical Outcomes in Women With Ductal Carcinoma In Situ
Shamliyan T, Wang SY, Virnig BA, Tuttle TM, Kane RL. Association Between Patient and Tumor Characteristics With Clinical Outcomes in Women With Ductal Carcinoma In Situ. JNCI Monographs 2010, 2010: 121-129. PMID: 20956815, PMCID: PMC5161074, DOI: 10.1093/jncimonographs/lgq034.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAgedBody Mass IndexBreast NeoplasmsCarcinoma, Intraductal, NoninfiltratingFemaleGonadal Steroid HormonesHumansMammographyMenopauseNeoplasm Recurrence, LocalNeoplasms, Hormone-DependentPrognosisRacial GroupsRandomized Controlled Trials as TopicReceptor, ErbB-2Receptors, EstrogenReceptors, ProgesteroneRiskSocioeconomic FactorsTreatment OutcomeTumor BurdenConceptsDuctal carcinomaClinical outcomesRecurrent cancerTumor characteristicsWorse outcomesNegative estrogen receptor statusAdvanced recurrent cancerPositive surgical marginsEstrogen receptor statusLarger tumor sizeHigh-risk categoryComposite prognostic indicesReceptor statusSurgical marginsPrognostic indexTumor sizeComedo necrosisPathological gradingClinical trialsObservational studyHigh riskHER2 receptorSynthesis of evidenceHigh mortalityYoung womenThe Impact of Surgery, Radiation, and Systemic Treatment on Outcomes in Patients With Ductal Carcinoma In Situ
Kane RL, Virnig BA, Shamliyan T, Wang SY, Tuttle TM, Wilt TJ. The Impact of Surgery, Radiation, and Systemic Treatment on Outcomes in Patients With Ductal Carcinoma In Situ. JNCI Monographs 2010, 2010: 130-133. PMID: 20956816, PMCID: PMC5161061, DOI: 10.1093/jncimonographs/lgq022.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsAntineoplastic Agents, HormonalAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, Intraductal, NoninfiltratingChemotherapy, AdjuvantCombined Modality TherapyDisease ProgressionFemaleHumansIncidenceMastectomyMastectomy, SegmentalNeoplasm Recurrence, LocalNeoplasms, Second PrimaryPrognosisRadiotherapy, AdjuvantRandomized Controlled Trials as TopicTamoxifenTreatment OutcomeConceptsBreast-conserving surgeryDuctal carcinomaInvasive carcinomaWhole breast radiation therapyImpact of surgeryTerms of recurrenceInvasive recurrenceRecurrent DCISDCIS recurrenceSystemic treatmentObservational studyRadiation therapyEquivalent outcomesCarcinomaMastectomyRecurrenceDCISSurgeryTamoxifenLower ratesOutcomesWomenLumpectomyPatientsMEDLINEIncorporating margin status information in treatment decisions for women with ductal carcinoma in situ: a decision analysis
Wang SY, Kuntz K, Tuttle T, Kane R. Incorporating margin status information in treatment decisions for women with ductal carcinoma in situ: a decision analysis. Breast Cancer Research And Treatment 2010, 124: 393-402. PMID: 20848183, DOI: 10.1007/s10549-010-1166-7.Peer-Reviewed Original ResearchMeSH KeywordsBreast NeoplasmsCarcinoma, Intraductal, NoninfiltratingDecision Support TechniquesFemaleHumansMarkov ChainsMastectomy, SegmentalMiddle AgedNeoplasm Recurrence, LocalPatient PreferencePatient SelectionQuality-Adjusted Life YearsRadiotherapy, AdjuvantRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeConceptsBreast-conserving surgeryQuality-adjusted life yearsRadiation therapyMargin statusDuctal carcinomaRT side effectsDecision-analytic Markov modelOne-way sensitivity analysesImportance of patientsProbabilistic sensitivity analysesDCIS treatmentInvasive recurrenceSalvage mastectomyOptimal treatmentHypothetical cohortTreatment decisionsLifetime horizonSide effectsLife yearsDCISPatientsWomenCarcinomaTreatment